

## Original Research Article

# The Effect of Required Injection Numbers During the First Year on the Clinical Course of Neovascular Age-related Macular Degeneration

### ABSTRACT:

**Aims:** To evaluate the effect of injection number of ranibizumab on an as-needed treatment regimen during the first year of treatment on the clinical course of neovascular age-related macular degeneration (nAMD).

**Study design:** Retrospective study.

**Place and Duration of Study:** Beyoglu Eye Training and Research Hospital. Department of Retina, between December 2009 and December 2011.

**Methodology:** The newly diagnosed nAMD patients who were treated with intravitreal ranibizumab on an as-needed treatment regimen with a follow-up period of at least 24 months were included in the study. The patients were divided into three groups according to the required injection numbers during the first year; group A, 3 injections; group B, 4-5 injections; group C  $\geq 5$  injections. Main outcome measures were the change in best corrected visual acuity (BCVA), and central retinal thickness (CRT). Secondary outcome measure was the number of injections during the second year.

**Results:** The study included 92 eyes of 87 patients. Group A consisted of 14 eyes (15.2%), group B consisted of 30 eyes (32.6%), and group C consisted of 48 eyes (52.2%). The visual outcomes seemed better in group A; however, there was not a statistically significant difference among the three groups in regards of change in BCVA at all of the time points ( $p=0.4$  for month 6,  $p=0.5$  for month 12,  $p=0.6$  for month 18,  $p=0.6$  for month 24). There was not a statistically significant difference among the three groups in regards of change in CRT at all of the time points ( $p=0.2$  for month 6,  $p=0.2$  for month 12,  $p=0.1$  for month 18,  $p=0.6$  for month 24). The mean number of injections at month 12 and 24 was statistically different among the three groups ( $p<0.0001$  for both).

**Conclusion:** This study showed a possible relationship between injection numbers and treatment outcomes in patients with nAMD on an as-needed treatment regimen. However there was not a statistically significance among the three groups.

**Keywords:** Age-related macular degeneration, as-needed treatment, ranibizumab, AMD

## 1. INTRODUCTION

Neovascular age-related macular degeneration (nAMD) is a leading cause of severe visual loss among elderly population in developed countries [1,2]. Historically, different treatment options like laser photocoagulation, photodynamic therapy, and vitreoretinal surgery were

studied for nAMD [3-9]. Currently, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have become the gold standard for the treatment of nAMD [10,11]. Several studies showed that ranibizumab was effective to prevent VA loss up to 95% of the patients, and is effective to make an improvement in VA up to 40% of the patients both with monthly and flexible treatment regimens [11-15].

Ranibizumab treatment originally was introduced as a monthly treatment regimen [9,10]. Later, some clinical and optical coherence tomography based flexible treatment regimens were described [11-13]. PRONTO was one of the most important studies which showed similar results with the previous studies and the regimen used in PRONTO study became very popular in a very short time [11]. Then came a question, are flexible treatments really as effective as monthly treatment? This question was addressed in CATT study, and in both ranibizumab and bevacizumab arms of the study, there was not a statistically significant difference between flexible and monthly treatment regimens in regards of change in visual acuity and central retinal thickness [13].

Theoretically, higher injection number may mean increased disease activity. In PRONTO study, this correlation was evaluated indirectly and no relationship was found between injection number and visual outcomes [11]. In this study, we aimed to evaluate the effect of first year injection number on the functional and anatomical outcomes of patients with nAMD who were on an as-needed treatment regimen with ranibizumab.

## 2. MATERIAL AND METHODS

The clinical data of the patients who were treated with ranibizumab between 2009 and 2011 were retrospectively evaluated for this study. Inclusion criteria were age of 50 years or more, newly diagnosed nAMD, no treatments received other than ranibizumab alone, and a minimum follow-up period of 24 months. Patients were not included if they had any of the following criteria: retinal diseases other than nAMD, previous intravitreal injections, or a history of photodynamic therapy or laser photocoagulation. The tenets of the Declaration of Helsinki were followed throughout the study, and written informed consent for the treatment was obtained from all patients.

### 2.1. Data:

Data collected from the patients' records included age, gender, type of choroidal neovascularization (CNV) (predominantly or minimally classic or occult), BCVA and central retinal thickness (CRT) before treatment, at month 6, 12, 18, and 24. The number of injections at month 12 and 24 were recorded for each patient. The patients were divided into three groups. Group A consisted of the patients who required only 3 injections, group B consisted of the patients who required 4 and 5 injections, and group C consisted of the patients who required >5 injections during the first year.

### 2.2. Examinations:

All patients underwent a standardized examination including measurement of BCVA via the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 4 meters, slit-lamp biomicroscopy and fundus examination, and measurement of intraocular pressure (IOP) via applanation tonometry. Fundus photography, fluorescein angiography (HRA-2; Heidelberg Engineering, Heidelberg, Germany), and optical coherence tomography (OCT) imaging (Stratus OCT TM; Carl Zeiss Meditec Inc., Dublin, CA, USA) were performed before treatment. All examinations were repeated monthly, except fluorescein angiography, which was repeated only when the cause of visual acuity deterioration could not be clarified with

the clinical examination and other imaging methods. OCT was used for detecting subretinal fluid and measurement of CRT, the latter being defined as the mean thickness of the neurosensory retina in the central 1 mm diameter region, computed via OCT mapping software provided with the device.

## 2.3. Injection method:

All injections were performed under sterile conditions after topical anesthesia and 10% povidone-iodine scrub (Betadine; Purdue Pharma, Stamford, CT, USA) was used on the lids and lashes, and then 5% povidone-iodine was administered on the conjunctival sac. Intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA, USA) or ranibizumab (Lucentis; Novartis, Basel, Switzerland) was injected with a 27-gauge needle through the pars plana at 3.5 mm to 4 mm posterior to the limbus. Patients were then instructed to consult the hospital if they experienced decreased vision, eye pain, or any new symptoms.

## 2.4. Treatment schedule:

For the first three months of treatment, all patients received monthly doses of ranibizumab (0.5 mg/0.05 ml). The patients were then examined monthly and were retreated if they met any of the following criteria: a) Visual loss of 1 or more lines, b) Newly developed macular hemorrhage, c) Evidence of CNV enlargement on examination or fluorescein angiography, d) Any amount of persistent subretinal fluid one month after an injection.

## 2.5. Data analysis:

Visual acuity was converted to logarithm of Minimum Angle of Resolution (LogMAR) for statistical analysis. One-way ANOVA test and following post-hoc test was used to compare categorical variables and  $\chi^2$  test/Fisher's exact test for nominal parameters. A p value of less than 0.05 was considered to be statistically significant. The statistical analysis was performed using SPSS version (Version 15.0, SPSS Inc., Chicago, IL, USA).

## 3. RESULTS

Nine-two eyes of 87 patients met the inclusion criteria for the study. The mean age of the patients was  $73.5 \pm 7.8$  years (range 53-89 years). Forty-two patients (48.3%) were male, 45 patients (51.7%) were female. Predominantly classic CNV was present in 21 eyes (22.8%), and occult/minimally classic CNV was present in 71 eyes (77.2%). The mean number of injections at month 12, and 24 was  $5.4 \pm 1.5$  (range 3-8), and  $8.0 \pm 2.9$  (range 3-15). There were 14 eyes (15.2%) in group A, 30 eyes in group B (32.6%), and 48 eyes (52.2%) in group C. The general characteristics of the patients were summarized in Table 1.

**Table 1. General characteristics of the patients.**

|                              | Overall        |
|------------------------------|----------------|
| Mean age, years              | $71.4 \pm 8.2$ |
| Gender (Male/Female)         | 36/43          |
| Laterality (Right /Left eye) | 38/41          |

|                                          |                  |
|------------------------------------------|------------------|
| <b>Lens status (Phakic/Pseudophakic)</b> | 59/19            |
| <b>CNV type (classic/occult)</b>         | 23/56            |
| <b>Mean baseline VA</b>                  | 0.85±0.41 LogMAR |
| <b>VA at month 12</b>                    | 0.72±0.46 LogMAR |
| <b>Mean VA at month 24</b>               | 0.73±0.49 LogMAR |
| <b>Mean injection number at month 12</b> | 5.4±1.5          |
| <b>Mean injection number at month 24</b> | 8.0±2.9          |
| <b>Mean</b>                              |                  |


102 CNV, choroidal neovascularization; VA, visual acuity.

103 The mean BCVA of the patients at different time points in the three groups were listed in  
 104 table 2 and showed in figure 1. The change in mean BCVA from baseline to month 6, 12, 18,  
 105 and 24 was statistically better in all of the three groups ( $p<0.05$ , for all). Although the visual  
 106 outcomes seemed better in group a, there was not a statistically significant difference among  
 107 the three groups in regards of change in BCVA at all of the time points ( $p=0.4$  for month 6,  
 108  $p=0.5$  for month 12,  $p=0.6$  for month 18,  $p=0.6$  for month 24).

109 **Table 2. Mean LogMAR visual acuity of the groups at different time points.**

|                  | <b>Group 1</b> | <b>Group 2</b> | <b>Group 3</b> | <b>P value</b> |
|------------------|----------------|----------------|----------------|----------------|
| <b>Baseline,</b> | 0.70±0.26      | 0.86±0.40      | 0.89±0.44      | 0.2            |
| <b>LogMAR</b>    |                |                |                |                |
| <b>Month 6,</b>  | 0.55±0.25      | 0.67±0.41      | 0.82±0.47      | 0.08           |
| <b>LogMAR</b>    |                |                |                |                |
| <b>Month 12,</b> | 0.48±0.29      | 0.69±0.44      | 0.80±0.49      | 0.07           |
| <b>LogMAR</b>    |                |                |                |                |
| <b>Month 18,</b> | 0.46±0.23      | 0.74±0.52      | 0.79±0.50      | 0.09           |
| <b>LogMAR</b>    |                |                |                |                |
| <b>Month 24,</b> | 0.47±0.21      | 0.73±0.52      | 0.81±0.51      | 0.08           |
| <b>LogMAR</b>    |                |                |                |                |

110



111

112 **Fig. 1. The changes in mean visual acuity in the three groups. The graph shows the**  
 113 **mean LogMAR visual acuity levels from baseline to month 24. The change in mean**  
 114 **best corrected visual acuity from the baseline to month 6, 12 18, and 24 was not**  
 115 **statistically different among the three groups ( $p>0.05$  for all).**

116 At month 24, 5 of the 14 patients (36 %) in group 1, 15 of the 30 patients ( 50 %) in group 2,  
 117 and 16 of the 48 patients (33%) in group 3 gained VA $\geq$ 3 lines. Fourteen of the 14 patients  
 118 (100 %) in group 1, 27 of the 30 patients ( 90 %) in group 2, and 37 of the 48 patients (77%)  
 119 in group 3 had stable or improved vision (loss of $<$ 3 line, or remained stable, or gained $\geq$ 1  
 120 lines). None of the patients in group 1, 3 of the 30 patients (10 %) in group 2, and 11 of the  
 121 48 patients (23 %) in group 3 had VA loss $\geq$ 3 lines.


122 The mean CRT at different time points in the three groups were listed in table 3 and showed  
 123 in figure 2. The change in mean CRT from baseline to month 6, 12, 18, and 24 was  
 124 statistically better in all of the three groups ( $p<0.05$ , for all). There was not a statistically  
 125 significant difference among the three groups in regards of change in CRT at all of the time  
 126 points ( $p=0.2$  for month 6,  $p=0.2$  for month 12,  $p=0.1$  for month 18,  $p=0.6$  for month 24).

127 **Table 3. Mean central retinal thickness of the groups at different time points.**

|                                    | Group 1      | Group 2      | Group 3      | P value |
|------------------------------------|--------------|--------------|--------------|---------|
| <b>Baseline,</b><br><b>microns</b> | 342 $\pm$ 89 | 354 $\pm$ 88 | 304 $\pm$ 97 | 0.06    |
| <b>Month 6,</b><br><b>microns</b>  | 257 $\pm$ 58 | 274 $\pm$ 93 | 262 $\pm$ 70 | 0.7     |
| <b>Month 12,</b><br><b>microns</b> | 261 $\pm$ 62 | 256 $\pm$ 71 | 253 $\pm$ 58 | 0.9     |
| <b>Month 18,</b><br><b>microns</b> | 232 $\pm$ 40 | 261 $\pm$ 70 | 257 $\pm$ 64 | 0.3     |

|                      |        |        |        |     |
|----------------------|--------|--------|--------|-----|
| Month 24,<br>microns | 235±36 | 267±80 | 266±73 | 0.3 |
|----------------------|--------|--------|--------|-----|

128



129

130 **Fig. 2. The changes in mean central retinal thickness in the three groups. The graph**  
 131 **shows the mean central retinal thickness levels from baseline to month 24. The**  
 132 **change in mean central retinal thickness from the baseline to month 6, 12 18, and 24**  
 133 **was not statistically different among the three groups ( $p > 0.05$  for all).**

134 The mean number of injections at month 12 was  $3.0 \pm 0$  in group 1,  $4.6 \pm 0.4$  (range 4-5) in  
 135 group 2, and  $6.6 \pm 0.7$  (range 6-8) in group 3 ( $p < 0.0001$ ). The mean number of injections at  
 136 month 24 was  $3.7 \pm 1.2$  (range 3-7) in group 1,  $7.2 \pm 1.5$  (range 5-11) in group 2, and  $9.8 \pm 2.3$   
 137 (range 6-15) in group 3 ( $p < 0.0001$ ).

138 No serious systemic or ocular complications were detected in any of the patients. Only mild  
 139 complications like punctate keratitis, subconjunctival hemorrhage, and transient mild anterior  
 140 uveitis were observed.

141

## 142 4. DISCUSSION

143

144 The predictive factors for the treatment outcomes of nAMD were evaluated in many studies  
 145 [16]. Single nucleotide polymorphism in the complement factor H gene, increasing age,  
 146 poorer visual acuity at baseline, larger CNV at baseline, previous PDT, presence of PED at  
 147 baseline, a delay for the treatment was found to be negative predictive factors for the  
 148 treatment of nAMD [16]. On contrast, the presence of a foveal pit, absence of a fibrous  
 149 tissue under the fovea, a normal retinal layer configuration on OCT, presence of a vital RPE  
 150 on autofluorescence imaging was reported to be positive predictors [16].

151 The number of injections was not evaluated in a detailed fashion before as a predictive  
 152 factor for the treatment outcomes of nAMD. In PRONTO study, the influence of reinjections  
 153 on the change in visual acuity was evaluated. The relationship was assessed with two  
 154 different statistical analyses, although no statistically significant correlation was found with  
 155 either analysis, the authors mentioned about a trend towards a possible correlation between  
 156 more frequent injections and worse visual outcome [11]. Ozkaya et al. reported that the  
 157 nAMD patients who did not require additional ranibizumab injections after the initial 3

injections during the first year of treatment was found to be associated with better visual outcomes [17].

In this study mean overall injection number 5.4 at month 12 and 8.0 at month 24 which was comparable with PRONTO study [11]. Also the rate of the patients who received only 3 loading injections were similar (15.2 % in our study and 17.5 % in PRONTO study) [11]. In addition 32.6% of the patients required 4-5 injections and 52.2% patients required >5 injections during the first year. The change in VA at month 12 was 2.2, 1.7 and 0.9 lines in group A, B, and C, respectively, and the change at month 24 was 2.3, 1.3 and 0.8 lines, respectively. The functional and anatomical outcomes were not statistically different among the three groups, but there was a trend towards a lower increase in visual acuity in group C. Also the rate of the patients who lost  $\geq 3$  lines of VA supported the phenomenon, none of the patients lost  $\geq 3$  lines of VA in group A; in contrast 23% of the patients lost  $\geq 3$  lines of VA in group C. However, we could not support this data because of the low number of patients. Clinically it is obvious that the group of nAMD patients who require more frequent ranibizumab injection on an as-needed treatment regimen represents the group of patients with an increased disease activity. More active disease may lead to more cellular damage and may cause worse visual and anatomical outcomes. In this study, we tried to evaluate this possible relationship. However, we could not obtain statistically significant results because of low number of patients which was the most important limitation of this study. In addition we did not evaluate the CNV type and size among the three groups, and another important limitation was the retrospective design.

## 5. CONCLUSION

In conclusion, this study did not show a possible relationship between injection numbers and treatment outcomes in patients with nAMD on an as-needed treatment regimen. However, the visual and anatomical results seemed better in the group of patients who required less ranibizumab injections without a statistically significance. Therefore, we think that this study may give rise to a further study that will evaluate the effects of injection number and injection frequency on the treatment outcomes of nAMD in a larger group of patients.

## REFERENCES

- [1] Laouar K, Dupeyron G, Audemard D, Arnaud B, Arndt C. [Quality of life in patients with wet age-related macular degeneration treated with photodynamic therapy]. J Fr Ophtalmol 2007;30:233-238. [Article in French]
- [2] Leveziel N, Delcourt C, Zerbib J, Dolfius H, Kaplan J, Benlian P et al. [Epidemiology of age related macular degeneration]. J Fr Ophtalmol 2009;32:440-451. [Article in French]
- [3] Donati G. [Current treatment of choroidal neovascularization in age-related macular degeneration]. J Fr Ophtalmol 2002;25:740-746. [Article in French]
- [4] Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-1231

- 204 [5] Kapran Z, Ozkaya A, Uyar OM. Hemorrhagic age-related macular degeneration managed  
205 with vitrectomy, subretinal injection of tissue plasminogen activator, gas tamponade, and  
206 upright positioning. *Ophthalmic Surg Lasers Imaging Retina* 2013;44:471-476.
- 207 [6] Donati G. [Cost-effectiveness of photodynamic therapy with verteporfin for choroidal  
208 neovascularization in age-related macular degeneration in routine clinical practise in  
209 Switzerland]. *J Fr Ophtalmol* 2007;30:837-841. [Article in French]
- 210 [7] Ozkaya A, Gurcan Z, Yigit U, Elmasas Gultekin O, Ozkaya HM. Photodynamic therapy  
211 results in age related macular degeneration. *Ret-Vit* 2010;4:289-296.
- 212 [8] van den Bergh H, Ballini JP, Sickenberg M. On the selectivity of photodynamic therapy of  
213 choroidal neovascularization associated with age-related macular degeneration. *J Fr*  
214 *Ophtalmol* 2004;27:75-78.
- 215 [9] Hajouli N, Hiesch A, Quintyn JC. [Triple therapy for the treatment of choroidal  
216 neovascularization with pigment epithelium detachment in age-related macular  
217 degeneration]. *J Fr Ophtalmol* 2010;33:487-492. [Article in French]
- 218 [10] Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al; MARINA  
219 Study Group. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med*  
220 2006;355:1419-1431.
- 221 [11] Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-  
222 dosing regimen with intravitreal ranibizumab for neovascular age-related macular  
223 degeneration: year 2 of the PrONTO Study. *Am J Ophthalmol* 2009;148:43-58.
- 224 [12] De Bats F, Grange JD, Cornut PL, Feldman A, Burillon C, Denis P, et al. Bevacizumab  
225 versus ranibizumab in the treatment of exudative age-related macular degeneration: a  
226 retrospective study of 58 patients. *J Fr Ophtalmol* 2000;35:661-666.
- 227 [13] CATT Research Group; Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and  
228 bevacizumab for neovascular age-related macular degeneration. *N Engl J Med*  
229 2011;364:1897-1908.
- 230 [14] Ozkaya A, Alkin Z, Karakucuk Y, Yasa D, Yazici AT, and Demirok A, "Bevacizumab  
231 versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related  
232 Macular Degeneration in Turkish Patients," *ISRN Ophthalmology*, vol. 2013, Article ID  
233 151027, 6 pages, 2013. doi:10.1155/2013/151027
- 234 [15] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, et  
235 al; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related  
236 Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.  
237 *Ophthalmology* 2013;120:2300-2309.
- 238 [16] Finger RP, Wickremasinghe SS, Baird PN, Guymer RH. Predictors of anti-VEGF  
239 treatment response in neovascular age-related macular degeneration. *Surv Ophthalmol*  
240 2014;59:1-18.
- 241 [17] Ozkaya A, Alkin Z, Osmanbasoglu OA, Ozkaya HM, Demirok A. Intravitreal ranibizumab  
242 for neovascular age-related macular degeneration patients with good baseline visual acuity  
243 and the predictive factors for visual outcomes. *J Fr Ophtalmol*. 2014 Apr;37(4):280-7.